|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.04.26 - 12:39
|
Novo Nordisk A/S - share repurchase programme (GlobeNewswire EN)
|
|
|
Bagsværd, Denmark, 13 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026....
|
|
|
|
|
13.04.26 - 08:48
|
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program (GlobeNewswire EN)
|
|
|
COPENHAGEN, Denmark, April 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to DKK 200 million in the period from March 12, 2026 to May 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....
|
|
|
|
|
10.04.26 - 18:12
|
Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader (24/7 Wall St.)
|
|
|
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early February, and the gap between them has widened significantly. Lilly's tirzepatide franchise is accelerating. Novo is cutting jobs, warning of a sales decline, and leaning on a newly launched pill to stabilize its position. Tirzepatide Pulls Away. Semaglutide Faces the ... Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader...
|
|
|
10.04.26 - 12:01
|
Novo Nordisk Neutral (DPA-AFX)
|
|
|
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Novo Nordisk mit einem Kursziel von 332 dänischen Kronen auf "Neutral" belassen. Die Verschreibungszahlen des Abnehmmittels Wegovy in Pillenform imponierten weiterhin, schrieb ......
|
|
|
|
|
10.04.26 - 08:15
|
Novo Nordisk: Auch das noch – Top-Forscherin geht (Der Aktionaer)
|
|
|
Novo Nordisk hat die Pole-Position im wachstumsstarken Adipositas-Markt aus der Hand gegeben. Der große US-Wettbewerber Eli Lilly ist inzwischen enteilt. Und nun muss Novo Nordisk auch noch den Abgang der Top-Forscherin Lotte Bjerre Knudsen hinnehmen, die maßgeblich die Entwicklung von Appetitzüglern bei den Dänen geprägt hat....
|
|
|
|
|
09.04.26 - 16:18
|
Global Weight Loss and Obesity Management Market | 12.8% CAGR Growth Trajectory | Asia Pacific, North America Lead | Novo Nordisk, Eli Lilly, Medtronic Drive Integrated Care Evolution (PR Newswire)
|
|
|
NEWARK, Del., April 9, 2026 /PRNewswire/ -- According to the latest analysis by Future Market Insights, the global weight loss and obesity management market is undergoing a transformative expansion, fueled by rising obesity prevalence, growing health awareness, and rapid innovation across......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
